246 related articles for article (PubMed ID: 32314924)
21. Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.
Zucconi BE; Makofske JL; Meyers DJ; Hwang Y; Wu M; Kuroda MI; Cole PA
Biochemistry; 2019 Apr; 58(16):2133-2143. PubMed ID: 30924641
[TBL] [Abstract][Full Text] [Related]
22. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy.
Dai Q; Yuan Z; Sun Q; Ao Z; He B; Jiang Y
Bioorg Med Chem Lett; 2024 May; 104():129742. PubMed ID: 38604299
[TBL] [Abstract][Full Text] [Related]
24. Characterization of novel inhibitors of histone acetyltransferases.
Eliseeva ED; Valkov V; Jung M; Jung MO
Mol Cancer Ther; 2007 Sep; 6(9):2391-8. PubMed ID: 17876038
[TBL] [Abstract][Full Text] [Related]
25. Small molecule modulators of histone acetyltransferase p300.
Balasubramanyam K; Swaminathan V; Ranganathan A; Kundu TK
J Biol Chem; 2003 May; 278(21):19134-40. PubMed ID: 12624111
[TBL] [Abstract][Full Text] [Related]
26. Probing the reaction coordinate of the p300/CBP histone acetyltransferase with bisubstrate analogs.
Karukurichi KR; Cole PA
Bioorg Chem; 2011 Feb; 39(1):42-7. PubMed ID: 21111442
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
28. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
[TBL] [Abstract][Full Text] [Related]
30. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model.
Zhu X; Li Q; Chang R; Yang D; Song Z; Guo Q; Huang C
PLoS One; 2014; 9(3):e91303. PubMed ID: 24603592
[TBL] [Abstract][Full Text] [Related]
31. Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases.
Ji Z; Clark RF; Bhat V; Matthew Hansen T; Lasko LM; Bromberg KD; Manaves V; Algire M; Martin R; Qiu W; Torrent M; Jakob CG; Liu H; Cole PA; Marmorstein R; Kesicki EA; Lai A; Michaelides MR
Bioorg Med Chem Lett; 2021 May; 39():127854. PubMed ID: 33631370
[TBL] [Abstract][Full Text] [Related]
32. Anti-histone acetyltransferase activity from allspice extracts inhibits androgen receptor-dependent prostate cancer cell growth.
Lee YH; Hong SW; Jun W; Cho HY; Kim HC; Jung MG; Wong J; Kim HI; Kim CH; Yoon HG
Biosci Biotechnol Biochem; 2007 Nov; 71(11):2712-9. PubMed ID: 17986787
[TBL] [Abstract][Full Text] [Related]
33. Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.
Sbardella G; Castellano S; Vicidomini C; Rotili D; Nebbioso A; Miceli M; Altucci L; Mai A
Bioorg Med Chem Lett; 2008 May; 18(9):2788-92. PubMed ID: 18434144
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
Xiong Y; Zhang M; Li Y
Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
[TBL] [Abstract][Full Text] [Related]
35. 4-Pyridone-3-carboxylic acid as a benzoic acid bioisostere: Design, synthesis, and evaluation of EP300/CBP histone acetyltransferase inhibitors.
Kanada R; Suzuki T; Murata T; Miyazaki M; Shimada T; Kuroha M; Minami M; Higuchi S; Tominaga Y; Naito H
Bioorg Med Chem Lett; 2021 Nov; 51():128358. PubMed ID: 34534674
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
[TBL] [Abstract][Full Text] [Related]
37. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors.
Sagar V; Zheng W; Thompson PR; Cole PA
Bioorg Med Chem; 2004 Jun; 12(12):3383-90. PubMed ID: 15158807
[TBL] [Abstract][Full Text] [Related]
38. The HTLV-1-encoded protein HBZ directly inhibits the acetyl transferase activity of p300/CBP.
Wurm T; Wright DG; Polakowski N; Mesnard JM; Lemasson I
Nucleic Acids Res; 2012 Jul; 40(13):5910-25. PubMed ID: 22434882
[TBL] [Abstract][Full Text] [Related]
39. Dissociable roles for histone acetyltransferases p300 and PCAF in hippocampus and perirhinal cortex-mediated object memory.
Mitchnick KA; Creighton SD; Cloke JM; Wolter M; Zaika O; Christen B; Van Tiggelen M; Kalisch BE; Winters BD
Genes Brain Behav; 2016 Jul; 15(6):542-57. PubMed ID: 27251651
[TBL] [Abstract][Full Text] [Related]
40. Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines.
Wang YM; Gu ML; Meng FS; Jiao WR; Zhou XX; Yao HP; Ji F
Int J Oncol; 2017 Dec; 51(6):1860-1868. PubMed ID: 29075795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
